Novartis delivers 12% sales and 21% core operating income growth from continuing
- Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance Novartis
- Novartis Raises Outlook After Sandoz Generics Spinoff Bloomberg Television
- Novartis delays Pluvicto filing as CEO spots industry ‘conundrum’ with FDA FiercePharma
- Novartis Expects $1 Billion in Revenue From This Cancer Drug This Year The Wall Street Journal
- Novartis lifts 2023 earnings forecast for third time Yahoo Finance
- View Full Coverage on Google News
Read More: Novartis delivers 12% sales and 21% core operating income growth from continuing